Unspecified Adult Solid Tumor, Protocol Specific Clinical Trial
Official title:
Safety and Efficacy of RO4929097 in Combination With Temsirolimus: A Pharmacokinetic and Pharmacodynamic Phase I Study in Patients With Advanced Solid Tumours With an Expansion of Cohort With Patients With Recurrent/Metastatic Endometrial and Renal Cell Cancers
This phase I trial is studying the side effects and best dose of giving gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus together in treating patients with advanced solid tumors. Gamma-secretase/Notch signalling pathway inhibitor RO4929097 and temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 18 |
Est. completion date | October 2013 |
Est. primary completion date | July 2013 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Meets one of the following sets of criteria: - Dose-escalation group: - Histologically and/or cytologically confirmed solid malignancy - Metastatic or unresectable disease - Disease for which standard curative or palliative measures do not exist or are no longer effective - Expansion group: - Histologically and/or cytologically confirmed endometrial (endometrioid, uterine papillary serious carcinoma, or carcinosarcoma) or renal cell cancer - Metastatic or unresectable disease - Disease for which standard curative or palliative measures do not exist or are no longer effective - Measurable or non-measurable disease - Measurable disease is defined as = 1 lesion that can be accurately measured in = 1 dimension (longest diameter to be recorded) as = 20 mm with conventional techniques or as = 10 mm with spiral CT scan - No known brain metastases - ECOG performance status (PS) 0-1 (Karnofsky PS 70-100%) - Life expectancy > 12 weeks - Leukocytes = 3,000/mm^3 - ANC = 1,500/mm^3 - Platelet count = 100,000/mm^3 - Hemoglobin = 90 g/L (or = 9 g/dL) - Total bilirubin normal - AST/ALT = 2.5 times upper limit of normal - Serum creatinine normal OR creatine clearance = 60 mL/min - Fasting cholesterol = 350 mg/dL (9.0 mmol/L) - Fasting triglycerides = 400 mg/dL (4.56 mmol/L) - No uncontrolled hypocalcemia, hypomagnesemia, hyponatremia, hypophosphatemia or hypokalemia defined as less than the lower limit of normal for the institution, despite adequate electrolyte supplementation - Note: it is acceptable to use corrected calcium when interpreting calcium levels - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use two effective forms of contraception (i.e., barrier contraception and one other method of contraception) for = 4 weeks before, during, and for = 12 months after completion of study therapy - Able to swallow medication - No malabsorption syndrome or other condition that would interfere with intestinal absorption - No diarrhea = grade 2 that is not under control with standard anti-diarrhea medications - No uncontrolled concurrent illness including, but not limited to, any of the following: - Ongoing or active infection - Symptomatic congestive heart failure - Unstable anginal pectoris - Cardiac arrhythmia other than chronic, stable atrial fibrillation - Psychiatric illness or social situations that would limit compliance with study medications - QTc = 450 msec in males and a QTc = 470 msec in females, as measured by ECG using Bazett formula - No history of risk factors for QT interval prolongation including, but not limited to, a family or personal history of any of the following: - Long QT syndrome - Torsades de pointes - Recurrent syncope without known etiology - Sudden unexpected death - No pre-existing significant pulmonary infiltrates of unknown origin - No serologic positivity for hepatitis A, B, or C or history of liver disease or other forms of hepatitis or cirrhosis - No HIV-positive patients on combination antiretroviral therapy - No history of allergic reactions attributed to compounds of similar chemical or biologic composition to gamma-secretase inhibitor RO4929097 or temsirolimus - Female patients may not donate ova during or after study treatment - Male patients may not donate sperm during and for = 12 months after completion of study treatment - Patients may not donate blood during and for = 12 months after completion of study treatment - Any number of prior therapies allowed - Recovered from side effects of previous systemic anticancer therapy to < CTCAE grade 2 toxicity (except alopecia) - Concurrent leuteinizing hormone-releasing hormone agonist allowed in patients with castration-resistant prostate cancer - No prior gamma-secretase inhibitor or any inhibitor of the PI3K/Akt/mTOR pathway - At least 4 weeks since prior radiotherapy or systemic therapy (6 weeks for carmustine, nitrosoureas, or mitomycin C) - Exceptions may be made for low-dose, non-myelosuppressive radiotherapy for symptomatic palliation - No other concurrent investigational agents - No concurrent medications with narrow therapeutic indices that are metabolized by cytochrome P450 (CYP450), including warfarin sodium (Coumadin®) - No concurrent medications that are strong inducers, inhibitors, or substrates of CYP3A4 - No antiarrhythmics or other concurrent medications with known potential to prolong QT interval - No concurrent food that may interfere with the metabolism of gamma-secretase inhibitor RO4929097, including grapefruit or grapefruit juice - No other concurrent anticancer agents or therapies |
Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Canada | Juravinski Cancer Centre at Hamilton Health Sciences | Hamilton | Ontario |
Canada | University Health Network-Princess Margaret Hospital | Toronto | Ontario |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) |
Canada,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Recommended phase II dose defined as the dose level at which less than or equal to 1 of 6 patients experienced DLT assessed using NCI CTCAE version 4.0 | 21 days | Yes | |
Primary | Safety profile assessed using NCI CTCAE version 4.0 | Frequency and severity of adverse events will be tabulated using counts and proportions detailing frequently occurring, serious and severe events of interest. Attempts to model associations between pharmacokinetic data with toxicity profiles will be performed primarily using descriptive statistics, however, logistic regression may be used if warranted. | Up to 4 weeks post-treatment | Yes |
Secondary | Objective response to treatment assessed using the RECIST criteria 1.1 | All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. | Up to 4 weeks post-treatment | No |
Secondary | Pharmacokinetic profiles | All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. | Pre-dose, 0.5, 1, 2, 4, 6 and 24 hours | No |
Secondary | Pharmacodynamic effects | All analyses will be considered exploratory and inference will be performed with appropriate caution. For all statistical tests, two-sided tests will be performed and no p-value adjustment performed due to the exploratory nature of these tests. A p-value of 0.05 or less will be considered statistically significant. | Up to 4 weeks post-treatment | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01828775 -
Palliative Care Intervention in Improving Quality of Life, Psychological Distress, and Communication in Patients With Solid Tumors Receiving Treatment
|
N/A | |
Terminated |
NCT01642342 -
Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors
|
Phase 1 | |
Completed |
NCT00002950 -
Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01705548 -
Hypofractionated Stereotactic Radiosurgery in Treating Patients With Large Brain Metastasis
|
N/A | |
Completed |
NCT02146222 -
VEGFR/PDGFR Dual Kinase Inhibitor X-82 and Docetaxel in Treating Patients With Solid Tumors
|
Phase 1 | |
Terminated |
NCT01602627 -
Hsp90 Inhibitor AUY922 in Treating Older Patients With Advanced Solid Malignancies
|
Phase 1 | |
Completed |
NCT01191216 -
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
Recruiting |
NCT00992303 -
Collecting Tissue Samples From Patients With Cancer Undergoing Radiation Therapy and Healthy Participants
|
||
Recruiting |
NCT01137825 -
Registry of Older Patients With Cancer
|
||
Suspended |
NCT00935090 -
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
|
N/A | |
Completed |
NCT00949949 -
Everolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable Solid Tumors Refractory to Standard Therapy
|
Phase 1 | |
Completed |
NCT00924651 -
Exercise in Lessening Fatigue Caused by Cancer in Patients Undergoing Chemotherapy
|
Phase 3 | |
Withdrawn |
NCT00937417 -
S0716 Vandetanib and Docetaxel in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00710632 -
Screening to Predict Weight Loss in Patients With Cancer
|
N/A | |
Completed |
NCT00544596 -
R-(-)-Gossypol Acetic Acid, Cisplatin, and Etoposide in Treating Patients With Advanced Solid Tumors or Extensive Stage Small Cell Lung Cancer
|
Phase 1 | |
Completed |
NCT00573690 -
Sorafenib Combined With Cisplatin and Etoposide or Carboplatin and Pemetrexed in Treating Patients With Metastatic Solid Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00436735 -
Nelfinavir in Treating Patients With Metastatic, Refractory, or Recurrent Solid Tumors
|
Phase 1 | |
Completed |
NCT00352443 -
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
|
Phase 1 | |
Completed |
NCT00121277 -
Vorinostat and Capecitabine in Treating Patients With Metastatic or Unresectable Solid Tumors
|
Phase 1 | |
Completed |
NCT00128622 -
Denileukin Diftitox Followed by Vaccine Therapy in Treating Patients With Metastatic Cancer
|
Phase 1 |